Travere Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $1.12 billion
- Book Value:
- Revenue TTM:
- $226.05 million
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Travere Therapeutics Inc had its IPO on 2012-11-08 under the ticker symbol TVTX.
The company operates in the Healthcare sector and Biotechnology industry. Travere Therapeutics Inc has a staff strength of 462 employees.
Shares of Travere Therapeutics Inc opened at $14.03 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $13.52 - $14.03, and closed at $13.81.
This is a -0.5% slip from the previous day's closing price.
A total volume of 905,932 shares were traded at the close of the day’s session.
In the last one week, shares of Travere Therapeutics Inc have slipped by -7.13%.
Travere Therapeutics Inc's Key Ratios
Travere Therapeutics Inc has a market cap of $1.12 billion, indicating a price to book ratio of 11.939 and a price to sales ratio of 5.5633.
In the last 12-months Travere Therapeutics Inc’s revenue was $226.05 million with a gross profit of $-31354000 and an EBITDA of $-258668992. The EBITDA ratio measures Travere Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Travere Therapeutics Inc’s operating margin was -132.71% while its return on assets stood at -24.74% with a return of equity of -225.07%.
In Q2, Travere Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 10.2%.
Travere Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-5.06 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Travere Therapeutics Inc’s profitability.
Travere Therapeutics Inc stock is trading at a EV to sales ratio of 5.1699 and a EV to EBITDA ratio of -4.9989. Its price to sales ratio in the trailing 12-months stood at 5.5633.
Travere Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $736.43 million
- Total Liabilities
- $135.71 million
- Operating Cash Flow
- Capital Expenditure
- $3.20 million
- Dividend Payout Ratio
Travere Therapeutics Inc ended 2023 with $736.43 million in total assets and $0 in total liabilities. Its intangible assets were valued at $736.43 million while shareholder equity stood at $116.49 million.
Travere Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $135.71 million in other current liabilities, 7000.00 in common stock, $-1186184000.00 in retained earnings and $900000.00 in goodwill. Its cash balance stood at $70.87 million and cash and short-term investments were $491.34 million. The company’s total short-term debt was $4,663,000 while long-term debt stood at $376.40 million.
Travere Therapeutics Inc’s total current assets stands at $542.06 million while long-term investments were $0 and short-term investments were $420.46 million. Its net receivables were $20.40 million compared to accounts payable of $19.92 million and inventory worth $18.77 million.
In 2023, Travere Therapeutics Inc's operating cash flow was $-23553000.00 while its capital expenditure stood at $3.20 million.
Comparatively, Travere Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Travere Therapeutics Inc stock is currently trading at $13.81 per share. It touched a 52-week high of $27.29 and a 52-week low of $27.29. Analysts tracking the stock have a 12-month average target price of $26.93.
Its 50-day moving average was $15 and 200-day moving average was $18.54 The short ratio stood at 8.16 indicating a short percent outstanding of 0%.
Around 103.3% of the company’s stock are held by insiders while 11326.7% are held by institutions.
Frequently Asked Questions About Travere Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company’s product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health’s National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.